ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock

Projektinformationen

ZENEO

ID Finanzhilfevereinbarung: 876000

DOI

10.3030/876000

Projekt abgeschlossen

EK-Unterschriftsdatum 5 Juli 2019

Startdatum 1 August 2019

Enddatum 30 November 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

CROSSJECT
France

Periodic Reporting for period 1 - ZENEO (ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock)

Berichtszeitraum: 2019-08-01 bis 2019-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Anaphylactic shock is a rare, severe and rapid onset allergic reaction that can be treated with the injection of Adrenaline, but if left untreated may cause death by asphyxia in 20 minutes. Adrenaline auto-injectors are needle-based pre-filled devices for self-injection into the muscle of the outer side of the thigh. User tests of some leading auto-injectors show a poor success rate after six weeks (42% or 43% depending on the auto-injectors), half of errors being that people do not wait long enough (above 3 seconds) while the needle injects inside the muscle.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

During the Feasibility Study period, Crossject finetuned the market approach and essential arguments, focusing on the market drivers and advantages versus current solutions and the cost to take ZENEO® Adrenaline to TRL9. A sales forecast for three years post-project was prepared based on market analysis.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Crossject has used a combination of cutting-edge technologies to develop ZENEO® in such a way that it is capable of injecting a tiny jet of Adrenaline through a patient’s skin by propelling it at very high pressure and speed. All in all ZENEO® has been developed to relieve fear of needles; eliminate all risks of injury; and perform a true intramuscular injection by non-healthcare professionals due to its quick, one-handed use, thus excluding any risk of contamination and pollution of needles disposal. Crossject aims to be a leader of emergency use drug –device pharmaceutical products to save lives simply.

image1.png